Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17674850 | 0.98 | HSD17B10 (0.40) | HSD17B10 | |
| SCHEMBL31329709 | 0.98 | HSD17B10 (0.40) | HSD17B10 | |
| SCHEMBL29565685 | 0.90 | HSD17B10 (0.33) | HSD17B10 | |
| SCHEMBL9820899 | 0.74 | ESR1 (0.34) | — | |
| SCHEMBL13252162 | 0.73 | HSD17B10 (0.31) | HSD17B10 | |
| SCHEMBL9820680 | 0.72 | ESR1 (0.33) | — | |
| SCHEMBL4012058 | 0.71 | SCN1A (0.39) | HSD17B10 | |
| SCHEMBL4748922 | 0.71 | SCN1A (0.39) | HSD17B10 | |
| SCHEMBL1814570 | 0.71 | SCN1A (0.42) | HSD17B10 | |
| SCHEMBL6756605 | 0.71 | CDK5 (0.35) | HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240166645-A1 | PYRIDOPYRIMIDINONE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2024-05-23 | — | — | US | claimed |
| EP-4289843-A1 | PYRIDOPYRIMIDINONE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2023-12-13 | — | — | EP | claimed |
| CN-114907341-A | Pyridopyrimidinone derivatives, and preparation method and application thereof | 武汉人福创新药物研发中心有限公司 | 2022-08-16 | — | — | CN | claimed |
| US-20260116922-A1 | HIGHLY STABLE OXYTOCIN DERIVATIVES | UNIVERSITAET WIEN (AT) | 2026-04-30 | — | — | US | disclosed |
| WO-2025093628-A1 | ANTIGENIC SYNTHETIC PROTEINS CONTAINING A TETRAZINE-AMINO ACID | VALANX BIOTECH GMBH (AT) | 2025-05-08 | — | — | WO | disclosed |
| CN-114981255-B | Process for preparing cyclic carbonates with exocyclic vinylidene groups | 巴斯夫欧洲公司 | 2025-01-07 | — | — | CN | disclosed |
| EP-4453003-A1 | HIGHLY STABLE OXYTOCIN DERIVATIVES | Universität Wien (AT) | 2024-10-30 | — | — | EP | disclosed |
| CN-118338898-A | Small molecule inhibitors of oncogenic CHD1L with preclinical anti-colorectal cancer activity | 科罗拉多州立大学董事会（法人团体） | 2024-07-12 | — | — | CN | disclosed |
| US-20240166645-A1 | PYRIDOPYRIMIDINONE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2024-05-23 | — | — | US | disclosed |
| EP-4342951-A1 | IMIDAZO[1,2-A]PYRIDINIUM DERIVATIVES | Universität Wien (AT) | 2024-03-27 | — | — | EP | disclosed |
| CN-112204117-B | Liquid-crystalline medium | 默克专利股份有限公司 | 2024-03-26 | — | — | CN | disclosed |
| US-20110130401-A1 | NEW CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-06-02 | — | — | US | disclosed |
| EP-2323986-A2 | HETOEROCYCLYL CARBONIC ACID AMIDES AS ANTIPROLIFERATIVE AGENTS, PDKL INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2011-05-25 | — | — | EP | disclosed |
| EP-2324012-A1 | NEW COMPOUNDS | Boehringer Ingelheim International GmbH (DE) | 2011-05-25 | — | — | EP | disclosed |
| EP-2321299-A2 | PYRIDONS AS PDK1 INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2011-05-18 | — | — | EP | disclosed |
| WO-2011039344-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN TYROSINE KINASE 2 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-04-07 | — | — | WO | disclosed |
| US-20110071158-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-03-24 | — | — | US | disclosed |
| US-20110059938-A1 | NEW CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-03-10 | — | — | US | disclosed |
| US-20100311721-A1 | COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-09 | — | — | US | disclosed |
| US-20090186901-A1 | CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240166645-A1 | PYRIDOPYRIMIDINONE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | SOS1, WEE1, SOS2 | HSD17B10 3122/4885 |
| US-20100311721-A1 | COMPOUNDS | CCNA1, MKI67, CCNT1 | HSD17B10 1330/4885 |
| US-20110071158-A1 | NEW COMPOUNDS | CCNA1, MKI67, CCNT1 | HSD17B10 2822/4885 |
| US-20090186901-A1 | CHEMICAL COMPOUNDS | OPRK1, OPRD1, OPRL1 | HSD17B10 1798/4885 |
| US-20110059938-A1 | NEW CHEMICAL COMPOUNDS | CCNA1, CCNT1, MKI67 | HSD17B10 2087/4885 |
| US-20110130401-A1 | NEW CHEMICAL COMPOUNDS | RB1, MKI67, CCNA1 | HSD17B10 3220/4885 |
| US-20260116922-A1 | HIGHLY STABLE OXYTOCIN DERIVATIVES | OXTR, CRH, TRHR | HSD17B10 3383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.